The global diabetes devices market was valued at USD 20.92 billion in 2018 and is expected to grow to USD 48.35 billion by 2032, with a compound annual growth rate (CAGR) of 6.2% throughout the forecast period. In 2018, North America led the market, holding a share of 40.54%.
The diabetes devices market is expanding steadily as the global prevalence of diabetes continues to rise. These devices play a crucial role in monitoring blood glucose levels and delivering insulin, helping patients manage their condition more effectively. The market includes a range of products such as blood glucose monitors, continuous glucose monitoring systems, insulin pumps, and pens. Technological advancements, growing patient awareness, and the adoption of digital health solutions are contributing to the increased demand for diabetes devices. However, high costs, limited access in low-income regions, and regulatory challenges act as barriers to widespread adoption. Despite these challenges, the diabetes devices market is expected to grow significantly across various regions, driven by innovation and increasing healthcare investments.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/diabetes-devices-market-100803
Market Segmentation
By product type, the diabetes devices market is segmented into blood glucose monitoring devices (self-monitoring blood glucose systems, continuous glucose monitoring systems) and insulin delivery devices (insulin pens, insulin pumps, jet injectors).
By end user, the market is segmented into hospitals, homecare settings, and diagnostic centers.
Based on distribution channels, it is divided into hospital pharmacies, retail pharmacies, and online sales platforms.
The wearable segment within continuous glucose monitors is gaining traction due to user convenience and real-time tracking capabilities.
Insulin pens continue to dominate the insulin delivery category due to their ease of use and lower cost compared to insulin pumps in the diabetes devices market.
List Of Key Companies Covered in Diabetes Devices Market:
Hoffmann-La Roche Ltd
Tandem Diabetes Care, Inc.
Braun Melsungen AG
Medtronic
BD
Novo Nordisk A/S
Abbott
Sanofi
Other players
Market Growth
The diabetes devices market is witnessing steady expansion due to the rising global burden of diabetes and advancements in glucose monitoring and insulin delivery technologies.
Growing patient awareness, increasing adoption of continuous glucose monitoring systems, and integration of digital health tools are driving demand in the diabetes devices market.
The shift toward minimally invasive and non-invasive devices is a key factor fueling the growth of the diabetes devices market.
Favorable reimbursement scenarios and government initiatives supporting diabetes management further contribute to market expansion.
Increasing prevalence of Type 1 and Type 2 diabetes across both developed and emerging economies continues to strengthen the diabetes devices market outlook.
Restraining Factors
High cost associated with advanced diabetes devices such as insulin pumps and CGMs limits adoption in price-sensitive markets.
Device-related complications and accuracy concerns in glucose monitoring may reduce user trust and hamper adoption.
Limited access to these devices in low-income and rural areas remains a major barrier to diabetes devices market penetration.
Regulatory challenges and delays in product approvals can impede the launch of innovative diabetes devices.
Technical issues such as device calibration, sensor errors, and connectivity problems may negatively impact the user experience.
Regional Analysis
North America leads the diabetes devices market, supported by a high diabetic population, strong healthcare infrastructure, and widespread use of advanced technologies.
Europe follows closely, driven by rising diabetes prevalence, supportive reimbursement policies, and growing investments in digital health tools.
Asia Pacific is emerging as a high-growth region for the diabetes devices market due to increasing awareness, large patient pool, and expanding healthcare access in countries like India and China.
Latin America shows moderate growth with gradual adoption of insulin delivery systems and glucose monitoring tools.
The Middle East & Africa region experiences slower growth due to limited access to advanced diabetes devices, but rising public health initiatives are gradually improving adoption.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com